Kits Eyecare Ltd. (KTYCF)
| Market Cap | 376.13M -1.2% |
| Revenue (ttm) | 156.45M +21.5% |
| Net Income | 3.97M +49.2% |
| EPS | 0.11 +46.0% |
| Shares Out | n/a |
| PE Ratio | 94.84 |
| Forward PE | 58.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,264 |
| Open | 11.76 |
| Previous Close | 11.35 |
| Day's Range | 11.00 - 11.76 |
| 52-Week Range | 7.74 - 16.38 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Kits Eyecare
Kits Eyecare Ltd. operates a digital eyecare platform in the United States and Canada. It offers progressive, polarized, and contact lenses, eyeglasses, and frames under the KITS brand, as well as distributes eyewear products of various brands. The company operates a network of optical e-commerce websites, including KITS.com, KITS.ca, OptiContacts.com, and ContactsExpress.ca. Kits Eyecare Ltd. was founded in 2002 and is headquartered in Vancouver, Canada. [Read more]
Financial Performance
In 2025, Kits Eyecare's revenue was 202.46 million, an increase of 27.06% compared to the previous year's 159.34 million. Earnings were 3.11 million, a decrease of -0.19%.
Financial numbers in CAD Financial StatementsNews
Kits Eyecare price target raised to C$26.50 from C$22 at Canaccord
Canaccord raised the firm’s price target on Kits Eyecare (KTYCF) to C$26.50 from C$22 and keeps a Buy rating on the shares.
Kits Eyecare Earnings Call Transcript: Q2 2026
Q2 saw 17.8% revenue growth and a return to profitability, driven by strong glasses sales, premium lens upgrades, and record operating cash flow. Guidance for Q3 projects continued momentum, with investments in innovation, retail, and insurance integration supporting future growth.
Kits Eyecare Earnings release: Q2 2026
Kits Eyecare released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Kits Eyecare Registration statement: Q2 2026
Kits Eyecare filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
Kits Eyecare Registration statement: Q2 2026
Kits Eyecare filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
Kits Eyecare Slides: Q2 2026
Kits Eyecare has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Kits Eyecare Transcript: Planet MicroCap Las Vegas 2026
Founded by industry veterans, the company has rapidly scaled revenue and profitability by leveraging a vertically integrated model and targeting millennial consumers. Online penetration in eyewear is accelerating, with repeat customers driving most revenue. Strategic marketing, a focus on customer experience, and selective physical retail support long-term growth ambitions.
Kits Eyecare price target lowered to C$23 from C$25 at Desjardins
Desjardins lowered the firm’s price target on Kits Eyecare (KTYCF) to C$23 from C$25 and keeps a Buy rating on the shares.
Kits Eyecare Earnings Call Transcript: Q1 2026
Q1 2026 delivered 23% revenue growth and record adjusted EBITDA, driven by a 61% surge in glasses revenue and expanding gross margins. Strategic reinvestment of a one-time tariff refund fueled customer acquisition, while guidance calls for 25%-30% annual growth in constant currency.
Kits Eyecare Earnings release: Q1 2026
Kits Eyecare released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Kits Eyecare Slides: Q1 2026
Kits Eyecare has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Kits Eyecare Registration statement: Q1 2026
Kits Eyecare filed a registration statement on May 6, 2026, providing details about a securities offering with the SEC.
Kits Eyecare Registration statement: Q1 2026
Kits Eyecare filed a registration statement on May 6, 2026, providing details about a securities offering with the SEC.
Kits Eyecare price target raised to C$25 from C$23 at Desjardins
Desjardins raised the firm’s price target on Kits Eyecare (KTYCF) to C$25 from C$23 and keeps a Buy rating on the shares.
Kits Eyecare Earnings Call Transcript: Q4 2025
Q4 and FY 2025 saw record revenue and profitability, driven by strong growth in glasses, contact lenses, and AI glasses, with expanding gross margins and high repeat customer rates. The company remains debt-free, well-capitalized, and is guiding for continued growth in 2026.
Kits Eyecare Earnings release: Q4 2025
Kits Eyecare released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Kits Eyecare Slides: Q4 2025
Kits Eyecare has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Kits Eyecare Registration statement: Q4 2025
Kits Eyecare filed a registration statement on March 4, 2026, providing details about a securities offering with the SEC.
Kits Eyecare Registration statement: Q4 2025
Kits Eyecare filed a registration statement on March 4, 2026, providing details about a securities offering with the SEC.
Kits Eyecare management to meet with Roth Capital
Meetings to be held in London January 27-28 hosted by Roth Capital.
Kits Eyecare downgraded to Speculative Buy from Buy at Cormark
Cormark analyst Kyle McPhee downgraded Kits Eyecare (KTYCF) to Speculative Buy from Buy with a C$21.50 price target
Kits Eyecare Earnings Call Transcript: Q3 2025
Record Q3 revenue grew 25% year-over-year, with strong Canadian performance and 12th straight positive Adjusted EBITDA quarter. KITS branded contact lenses and premium lenses drove high-margin growth, while U.S. investment is set to resume as market conditions stabilize.
Kits Eyecare Earnings release: Q3 2025
Kits Eyecare released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
Kits Eyecare Slides: Q3 2025
Kits Eyecare has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Kits Eyecare Registration statement: Q3 2025
Kits Eyecare filed a registration statement on November 6, 2025, providing details about a securities offering with the SEC.